You just read:

Phase III Novartis Data Show Potential Benefit of Afinitor® Plus Sandostatin® LAR Depot in Patients with Advanced Carcinoid Tumors

News provided by

Novartis Pharmaceuticals Corporation

Oct 11, 2010, 04:53 ET